Lithium, an effective treatment for mania and the prevention of recurrent episodes of both mania and depression in patients with manic depressive illness, exerts multiple biochemical effects. However, any clinically relevant site of action of lithium must occur at therapeutic concentrations attained in the brain of patients and must account for the lag period accompanying onset of action as well as effects persisting beyond discontinuation of treatment. This monovalent cation acts as a potent uncompetitive inhibitor in the receptor-coupled breakdown of inositol phospholipids, resulting in a relative depletion of inositol and an alteration in the generation of diacylglycerol, an endogenous activator of protein kinase C. In our laboratory, we are examining the action of chronically administered lithium on posttranslational modification of specific phosphoproteins involved in regulating signal transduction in the brain. We have found that chronic, but not acute, administrationof lithium in rats markedly reduces a major phosphoproteinsubstrate of protein kinase C in the hippocampus, an effect that persists beyond the cessation of lithium treatment. This protein, myristoylated alanine-rich C kinase substrate ("MARCKS"), is implicated in synaptic neurotransmission, calcium regulation, and cytoskeletal restructuring. These findings have relevance for the long-term action of lithium in stabilizing an underlying dysregulation in the brain and may move us closer to formulating a molecular basis of manic depressive illness.
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HIstorIcal Perspective
Lithium was discovered as an element in 1817 and has been used to treat a multitude of somatopsychic disorders over the years (1). In particular, because lithium forms the most soluble salt known with uric acid, it was proposed as early as the mid-l9th century as a treatment for gout or "uric acid diathesis," which was described as including mood-related symptoms ranging from "gouty mania" to depression.
By However, there is now clear evidence that as many as 50% of such patients will experience a recurrence of either a manic or depressive episode within 5 months, with a clearly higher risk for a manic episode early in the withdrawal period (9, 10). Lithium also has a rather narrow therapeutic index, clinical toxicity being evident in some patients at plasma concentrations 50%
greater than the therapeutic range; thus, its therapeutic action may be on a continuum with some of its toxic manifestations. Our laboratory has been interested in addressing the biological targets responsible for the longterm therapeutic action of lithium in the brain.
Mechanism of Action
The underlying biological processes responsible for the episodic clinical manifestation of mania and depression may be related to faulty homeostatic regulation in the brain (6) . Patients with this disorder may lack the necessary system flexibility to adaptively respond to the periodic fluctuations in the internal and external state, but instead experience sudden oscillations beyond immediate compensatory control (11, 12) . This system failure results in the clinical manifestations of disruption of behavior and profound changes in mood, circadian rhythm, and neurophysiology of sleep, as well as significant alterations in neuroendocrine regulation, all consistent with a dysregulation within the limbic system and associated regions of the brainstem and prefrontal cortex. A better understanding of the molecular mechanisms by which lithium achieves its mood stabifization properties in these regions of the brain might not only lead to the development of even better psychopharmacological treatment approaches but also bring us closer to a molecular basis of the disorder itself. This research strategy has the advantage of focussing the investigator within the complex array of neurochemical systems within the brain, but has limitations in terms of extrapolation to the pathogenesis of the disorder, as will be discussed below.
Signal Transduction
Regulation of signal transduction within limbic and limbic-related regions of the brain, altering the balance of activity of the complex network of neurotransmitter pathways, remains an attractive site for the therapeutic action of a drug like lithium. Over the past several years, emerging data have confirmed that the phosphoinositide second-messenger system is an important site of action of lithium in the brain (see Fig. 1) (13, 14) . 
Intracellularcalcium.DAGisan endogenousactivatorofproteinkinase C (PKC).
Lithium inhibitsthe enzyme inositol monophosphatase,which prevents the recyding of inositol and increasesaccumulationof metabolitesin the DAG path- mm after the addition of carbachol) and could be significantly reduced by the addition of inositol. We have also observed that CMP-PA formation in cells grown and assayed in standard Ham's F12 medium supplemented with fetal bovine serum (100 milL) was markedly less than in cells grown in inositol-depleted media. substrates for PKC in the soluble and membrane fractions from hippocampi of control animals and animals given chronic lithium treatment (4 weeks), as well as from rats treated acutely with lithium (2 h) and rats withdrawn from chronic lithium administration for 40 h. We found a significant reduction (45%) in the in vitro phosphorylation of a prominent protein with an apparent molecular mass of 83 kDa in the soluble fraction of hippocampi from animals subjected to chronic lithium treatment (37). Other phosphoproteins, including other PKC substrates, were not changed by the chronic lithium treatment. Animals acutely achieving similRr therapeutic concentrations of lithium in the brain did not demonstrate a significant change in phosphorylation of these proteins. Animals withdrawn from lithium showed a partial reversal of the effects on the 83-kDa protein seen during chronic lithium treatment. The phosphoprotein appeared to correspond to a major myristoylated alanine-rich C kinase substrate (MARCKS) in brain. This was subsequently confirmed by using an antibody raised to highly purified MARCKS that recognizes both phosphorylated and nonphosphorylated forms of the protein. Western blot analyses provided evidence for a marked reduction in the amount of MARCKS in both the soluble (57%) and membrane (7 1%) fraction from hippocampus of rats receiving chronic lithium treatment (Table 1) . However, there was no such evidence for a reduction of MARCKS in rats receiving acute doses of lithium, and the reduction observed in the hippocampus of rats receiving repeated doses of lithium was stifi present at 40 h after abrupt discontinuation of the lithium diet. These findings ap- of glucose transport that we will eventually discover the etiological processes underlying the disease. Similarly, with the identification of the molecular target(s) directly associated with the longterm clinical efficacy of lithium, we will be in a position to better design future strategies for drug development and, in concert with molecular genetic approaches, to address the ultimate pathogenesis of manic depressive illness.
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